{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T06:50:33Z","timestamp":1768027833197,"version":"3.49.0"},"reference-count":19,"publisher":"Japan Endocrine Society","issue":"1","funder":[{"name":"National Health Commission Capacity Building and Continuing Education Center\u2019s Cancer Pain Management Project","award":["PTM1001-8"],"award-info":[{"award-number":["PTM1001-8"]}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024M753868"],"award-info":[{"award-number":["2024M753868"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chongqing Medical Young Top Talents Project"},{"name":"Chongqing Natural Science Foundation Project","award":["CSTB2025NSCQGPX0007"],"award-info":[{"award-number":["CSTB2025NSCQGPX0007"]}]},{"name":"Chongqing Medical Scientific Research Project","award":["2023QNXM018"],"award-info":[{"award-number":["2023QNXM018"]}]},{"name":"Chongqing Shapingba District 2024 Technology Innovation Project","award":["2024114"],"award-info":[{"award-number":["2024114"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1507\/endocrj.ej25-0295","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T22:08:28Z","timestamp":1760047708000},"page":"93-99","source":"Crossref","is-referenced-by-count":1,"title":["Sintilimab-related fulminant autoimmune diabetes mellitus manifesting as diabetic ketoacidosis and rare insulin resistance: A case report and literature review"],"prefix":"10.1507","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5452-5994","authenticated-orcid":false,"given":"Junhui","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Geriatric Oncology, Department of Palliative Care, Chongqing University Cancer Hospital, Chongqing, China"},{"name":"Endocrinology Department, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuping","family":"Zhang","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Deng","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liling","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Geriatric Oncology, Department of Palliative Care, Chongqing University Cancer Hospital, Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjing","family":"Yang","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Geriatric Oncology, Department of Palliative Care, Chongqing University Cancer Hospital, Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9985-1037","authenticated-orcid":false,"given":"Huiqing","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Geriatric Oncology, Department of Palliative Care, Chongqing University Cancer Hospital, Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2942-4511","authenticated-orcid":false,"given":"Bing","family":"Chen","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6456-7573","authenticated-orcid":false,"given":"Jiongyu","family":"Hu","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 von Mehren M, Kane JM, Agulnik M, Bui MM, Carr-Ascher J, et al. (2022) Soft tissue sarcoma, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 20: 815\u2013833.","DOI":"10.6004\/jnccn.2022.0035"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Keung EZ, Burgess M, Salazar R, Parra ER, Rodrigues-Canales J, et al. (2020) Correlative analyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to pembrolizumab. Clin Cancer Res 26: 1258\u20131266.","DOI":"10.1158\/1078-0432.CCR-19-1824"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3 Shao W, Yang K, Lu D, Gao Y, Zhang J, et al. (2025) Endocrine adverse reactions of tyrosine kinase inhibitors in combination with immune checkpoint inhibitors. <i>J Clin Endocrinol Metab<\/i> doi: 10.1210\/clinem\/dgaf117 Online ahead of print.","DOI":"10.1210\/clinem\/dgaf117"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Imagawa A, Hanafusa T, Awata T, Ikegami H, Uchigata Y, et al. (2012) Report of the committee of the Japan diabetes society on the research of fulminant and acute-onset type 1 diabetes mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus (2012). J Diabetes Investig 3: 536\u2013539.","DOI":"10.1111\/jdi.12024"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Jayathilaka B, Mian F, Franchini F, Au-Yeung G, IJzerman M (2025) Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review. Br J Cancer 132: 51\u201357.","DOI":"10.1038\/s41416-024-02887-1"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Panagi M, Pilavaki P, Constantinidou A, Stylianopoulos T (2022) Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness. Theranostics 12: 6106\u20136129.","DOI":"10.7150\/thno.72800"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Suijkerbuijk KPM, van Eijs MJM, van Wijk F, Eggermont AMM (2024) Clinical and translational attributes of immune-related adverse events. Nat Cancer 5: 557\u2013571.","DOI":"10.1038\/s43018-024-00730-3"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Zhou X, Yao Z, Bai H, Duan J, Wang Z, et al. (2021) Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncol 22: 1265\u20131274.","DOI":"10.1016\/S1470-2045(21)00333-8"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Takada S, Hirokazu H, Yamagishi K, Hideki S, Masayuki E (2020) Predictors of the onset of type 1 diabetes obtained from real-world data analysis in cancer patients treated with immune checkpoint inhibitors. Asian Pac J Cancer Prev 21: 1697\u20131699.","DOI":"10.31557\/APJCP.2020.21.6.1697"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Ruiz-Esteves KN, Shank KR, Deutsch AJ, Gunturi A, Chamorro-Pareja N, et al. (2024) Identification of immune checkpoint inhibitor-induced diabetes. JAMA Oncol 10: 1409\u20131416.","DOI":"10.1001\/jamaoncol.2024.3104"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Liu J, Shi Y, Liu X, Zhang D, Zhang H, et al. (2022) Clinical characteristics and outcomes of immune checkpoint inhibitor-induced diabetes mellitus. Transl Oncol 24: 101473.","DOI":"10.1016\/j.tranon.2022.101473"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12 Wright JJ, Salem JE, Johnson DB, Lebrun-Vignes B, Stamatouli A, et al. (2018) Increased reporting of immune checkpoint inhibitor-associated diabetes. Diabetes Care 41: e150\u2013e151.","DOI":"10.2337\/dc18-1465"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Cho YK, Jung CH (2023) Immune-checkpoint inhibitors-induced type 1 diabetes mellitus: from its molecular mechanisms to clinical practice. Diabetes Metab J 47: 757\u2013766.","DOI":"10.4093\/dmj.2023.0072"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Wei HH, Lai YC, Lin G, Lin CW, Chang YC, et al. (2024) Distinct changes to pancreatic volume rather than pancreatic autoantibody positivity: insights into immune checkpoint inhibitors induced diabetes mellitus. Diabetol Metab Syndr 16: 26.","DOI":"10.1186\/s13098-024-01263-6"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Dietsche KB, Magge SN, Dixon SA, Davis FS, Krenek A, et al. (2024) Glycemia and gluconeogenesis with metformin and liraglutide: a randomized trial in youth-onset type 2 diabetes. J Clin Endocrinol Metab 109: 1361\u20131370.","DOI":"10.1210\/clinem\/dgad669"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Szymczak-Pajor I, Wenclewska S, \u015aliwi\u0144ska A (2022) Metabolic action of metformin. Pharmaceuticals (Basel) 15: 810.","DOI":"10.3390\/ph15070810"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Chen XM, Zhang WQ, Tian Y, Wang LF, Chen CC, et al. (2018) Liraglutide suppresses non-esterified free fatty acids and soluble vascular cell adhesion molecule-1 compared with metformin in patients with recent-onset type 2 diabetes. Cardiovasc Diabetol 17: 53.","DOI":"10.1186\/s12933-018-0701-4"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Anholm C, Kumarathurai P, J\u00fcrs A, Pedersen LR, Nielsen OW, et al. (2019) Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease. Diabetol Metab Syndr 11: 42.","DOI":"10.1186\/s13098-019-0438-6"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Zhang A, Zhang X, Yang A, Dong S, Wang L, et al. (2025) Effects of SGLT2 inhibitors and GLP-1 receptor agonists on glycemic variability, islet cell function, and insulin resistance in patients with type 2 diabetes mellitus and renal cell carcinoma. Am J Cancer Res 15: 946\u2013965.","DOI":"10.62347\/OLUR1927"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/73\/1\/73_EJ25-0295\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T03:41:58Z","timestamp":1768016518000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/73\/1\/73_EJ25-0295\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej25-0295","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"EJ25-0295"}}